MSB 4.02% $1.25 mesoblast limited

Cell Therapy News/Articles, page-3197

  1. 3,851 Posts.
    lightbulb Created with Sketch. 1311
    A little bit of background news on our supplier Lonza.

    Today Lonza announced a new CEO, effective 1 November 2020

    The incoming CEO is Pierre-Alain Ruffieux. Below are some cherry picked quotes to illustrate where Lonza fits in with other BioPharma with bold for emphasis.

    "Pierre-Alain is currently Head of Global Pharma Technical Operations at Roche where he and his 12,000-strong team are responsible for all aspects of pharmaceutical commercial manufacturing and supply chain operations, technical, quality assurance and regulatory. Prior to that he held roles of increasing seniority at Novartis and has over 20 years’ experience in biopharmaceuticals."

    "Pierre-Alain Ruffieux, incoming Chief Executive Officer added: “I am delighted to have been appointed as CEO of Lonza. Having been a customer over many years, I greatly admire Lonza’s technology and people. I look forward to building on its many successes in the years to come.”"

    "About Lonza
    ...
    We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets."

    The above selected quotes are from;
    http://e3.marco.ch/publish/lonza/551_1215/20200604_Press_Release_CEO_Appointment_FINAL.pdf
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.25
Change
-0.053(4.02%)
Mkt cap ! $1.432B
Open High Low Value Volume
$1.27 $1.30 $1.17 $16.47M 13.35M

Buyers (Bids)

No. Vol. Price($)
13 86330 $1.25
 

Sellers (Offers)

Price($) Vol. No.
$1.26 91990 8
View Market Depth
Last trade - 14.07pm 24/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.